Skip to main content
SpringerLink
Log in

Dolutegravir-based regimen good use of resources for initial treatment of HIV 1 infection in Cameroon

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries

  2. Agence Nationale de Recherche sur le SIDA (French National Agency for AIDS Research)

Reference

  • Bousmah M-Q, et al. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial). PharmacoEconomics : 23 Dec 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00987-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolutegravir-based regimen good use of resources for initial treatment of HIV 1 infection in Cameroon. PharmacoEcon Outcomes News 869, 10 (2021). https://doi.org/10.1007/s40274-021-7377-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7377-9

Search

Navigation